/
Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company dedicated to the development of innovative powder-based intranasal therapies. The company’s primary focus is addressing acute medical conditions and urgent public health needs, utilizing proprietary microsphere technology to enable rapid, non-invasive drug delivery. Its product portfolio targets critical emergency situations, such as opioid overdose and anaphylactic shock, where immediate intervention is vital. Intranasal administration provides rapid absorption, ease of use, and does not require injection, making treatments more accessible to patients, caregivers, and first responders. Nasus Pharma’s technology has demonstrated significantly enhanced absorption rates compared to traditional solution-based drugs, supporting its relevance in life-threatening scenarios. Headquartered in Israel, the company’s work is particularly significant for advancing care standards in emergency medicine and holds potential for broader applications in the healthcare sector by improving the speed and effectiveness of drug delivery in acute settings.
$3.01
$0.06 (-1.95%)
EOD Jul 17, 2026
ROIC dropped from -39.99% to -165.28%, capital efficiency is deteriorating. Negative free cash flow of -$5M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$6M
▼ -282.2% YoY
Op. Margin
—
ROIC
-165.28%
▼ -125.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$5M
▼ -641.7% YoY
Op. Cash Flow (TTM)
-$5M
▼ -639.5% YoY
Net Debt
-$4M
Net Cash Position
Cash & Equiv.
$4M
Continue Research
Nasus Pharma (NSRX)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Nasus Pharma scores 20/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Nasus Pharma scores 20 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -165.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh NSRX's valuation and scores 20/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.